We are a clinical-stage biopharmaceutical company focused on developing therapies to improve the lives of patients diagnosed with cancer in ways that are truly meaningful to them.
When it comes to combatting cancer, we realize there are no “one size fits all” treatment approaches. We understand that every cancer lives in an intricate and complex microenvironment, creating significant unmet needs which must be addressed. It’s why we remain open to new ideas but selectively pursue science with the potential to make a significant impact for physicians, patients and their caregivers.
With deep expertise, agility and purpose, we are identifying and advancing late-stage, first-in-class clinical assets to market.
We are concentrating on a portfolio of small molecule drugs inhibiting critical signaling pathways in cancer, including the phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK) pathways. These signaling pathways are abnormal in cancer and promote tumor survival. Preclinical research has shown these pathways also contribute to the protective nature of the tumor microenvironment, thereby limiting the effectiveness of existing cancer treatments.